文献速递消化系统肿瘤

利用WNT通路激活与天冬酰胺酶的相互作用治疗结直肠癌

Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy.
PubMed 文献 · Cancer Discov · 2020-07-23

结直肠癌常由WNT/β-catenin信号激活驱动,但直接抑制WNT存在靶向毒性。研究发现,天冬酰胺酶对R-spondin融合的结直肠癌疗效显著,而对APC或β-catenin突变者效果差;药物抑制GSK3α可使后两者对天冬酰胺酶敏感,且不影响正常肠祖细胞。

要点

  • 天冬酰胺酶对R-spondin融合结直肠癌有显著毒性。
  • APC或β-catenin突变结直肠癌对天冬酰胺酶不敏感。
  • GSK3α抑制可增敏APC/β-catenin突变肿瘤而不影响正常肠祖细胞。

核心结论

  • WNT激活突变(如R-spondin融合)可赋予结直肠癌对天冬酰胺酶的治疗脆弱性。
  • 药物抑制GSK3α可扩展天冬酰胺酶敏感性至APC或β-catenin突变结直肠癌。

研究设计与样本

  • 基于前期白血病模型预测,在结直肠癌中验证WNT激活突变与天冬酰胺酶敏感性的关系。
  • 利用R-spondin融合(上游)与APC/β-catenin突变(下游)的结直肠癌模型进行遗传学区分。

主要发现

  • 天冬酰胺酶对APC或β-catenin突变结直肠癌疗效甚微。
  • 天冬酰胺酶对R-spondin融合结直肠癌具有深刻毒性。
  • 药物抑制GSK3α足以使APC或β-catenin突变结直肠癌对天冬酰胺酶敏感。
  • GSK3α抑制未使正常肠祖细胞对天冬酰胺酶敏感。

临床怎么用

  • R-spondin融合可作为天冬酰胺酶治疗结直肠癌的潜在生物标志物。
  • 对APC或β-catenin突变结直肠癌,联合GSK3α抑制可能增强天冬酰胺酶疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Colorectal cancer is driven by mutations that activate canonical WNT/β-catenin signaling, but inhibiting WNT has significant on-target toxicity, and there are no approved therapies targeting dominant oncogenic drivers. We recently found that activating a β-catenin-independent branch of WNT signaling that inhibits GSK3-dependent protein degradation induces asparaginase sensitivity in drug-resistant leukemias. To test predictions from our model, we turned to colorectal cancer because these cancers can have WNT-activating mutations that function either upstream (i.e., R-spondin fusions) or downstream (APC or β-catenin mutations) of GSK3, thus allowing WNT/β-catenin and WNT-induced asparaginase sensitivity to be unlinked genetically. We found that asparaginase had little efficacy in APC or β-catenin-mutant colorectal cancer, but was profoundly toxic in the setting of R-spondin fusions. Pharmacologic GSK3α inhibition was sufficient for asparaginase sensitization in APC or β-catenin-mutant colorectal cancer, but not in normal intestinal progenitors. Our findings demonstrate that WNT-induced therapeutic vulnerabilities can be exploited for colorectal cancer therapy. SIGNIFICANCE: Solid tumors are thought to be asparaginase-resistant via de novo asparagine synthesis. In leukemia, GSK3α-dependent protein degradation, a catabolic amino acid source, mediates asparaginase resistance. We found that asparaginase is profoundly toxic to colorectal cancers with WNT-activating mutations that inhibit GSK3. Aberrant WNT activation can provide a therapeutic vulnerability in colorectal cancer.See related commentary by Davidsen and Sullivan, p. 1632.This article is highlighted in the In This Issue feature, p. 1611.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Hinze L, Labrosse R, Degar J, et al. Exploiting the Therapeutic Interaction of WNT Pathway Activation and Asparaginase for Colorectal Cancer Therapy. Cancer Discov. 2020. PMID: 32703769. doi:10.1158/2159-8290.CD-19-1472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。